Manufacturing-aware generative models enable petascale synthesis of designed DNA - @lizbwood.bsky.social @jura.bsky.social go.nature.com/3NxXt1I
Ever wondered what it'd be like to run a de novo antibody campaign against 100 of the hardest targets, simultaneously, with 76% success rate, and have the complete wetlab validated results days from the project's start? We show you what that looks like, too: www.jurabio.com/mesa
A generative modeling framework enables large-scale designed DNA synthesis, yielding candidate cell therapies.
We are at the #StartupVillage at #EurIPS today — come say hi 👋
@jura.bsky.social
This constraint has shaped every aspect of how drug discovery operates: the emphasis on computational scoring, the reliance on expert intuition, the months of debate about which designs deserve the scarce resource of actual synthesis.
But prediction is valuable when verification is expensive.
Prediction is overhead when verification is cheap.
We've spent years building a system where verification is cheap -- generationally so.
This changes the logic of discovery in ways that are easy to underestimate. I tried to write a little about what that means: www.jurabio.com/blog/onebill...
JURA is launching a new target intelligence dashboard called MESA jurabio.com/mesa with a nice interactive case study from our recent TCRm campaigns. Go check it out -- we'll open to crowd-sourced targets soon. @jura.bsky.social
